1032-67-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(2-oxo-2-phenylethyl)isoindole-1,3-dione is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its phthalimide group allows for versatile chemical reactions, making it a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(2-oxo-2-phenylethyl)isoindole-1,3-dione is utilized as a building block for the preparation of complex organic molecules. Its unique structure and functional groups enable the formation of diverse chemical entities, contributing to the advancement of organic chemistry.
Used in the Preparation of Biologically Active Molecules:
2-(2-oxo-2-phenylethyl)isoindole-1,3-dione is employed as a precursor in the synthesis of biologically active molecules, such as pharmaceuticals, agrochemicals, and other bioactive compounds. Its structural features and reactivity make it a promising candidate for the development of novel molecules with potential therapeutic or biological applications.

InChI:InChI=1/C16H11NO3/c18-14(11-6-2-1-3-7-11)10-17-15(19)12-8-4-5-9-13(12)16(17)20/h1-9H,10H2

Upstream product

• 85-44-9 phthalic anhydride 
• 5468-37-1 2-aminoacetophenone hydrochloride 
• 6780-38-7 N-phthaloylglycine chloride 
• 71-43-2 benzene 
• 64-17-5 ethanol 
• 1074-82-4 potassium phtalimide 
• 70-11-1 α-bromoacetophenone 
• 136918-14-4 phthalimide 
• 86451-26-5 2,2'-(phenyl-λ³-iodanediyl)bis(isoindoline-1,3-dione) 
• 98-86-2 acetophenone 
• 114196-61-1 C₂₆H₂₂NOP 
• 88-95-9 Phthaloyl dichloride 
• 35645-98-8 2-(2-hydroxy-2-phenyl-ethyl)-isoindole-1,3-dione 
• 107-13-1 acrylonitrile 

Downstream Products

• 117439-99-3 2-phenyl-3-phthalimido-quinoline-4-carboxylic acid 
• 14498-33-0 2-(phenacylcarbamoyl)benzoic acid 
• 201797-77-5 N-(2,5-Dioxo-4-phenyl-imidazolidin-4-ylmethyl)-phthalamic acid 
• 54153-51-4 2-amino-3-cyano-4-phenylpyrrole 
• 54760-14-4 N-(3-cyano-4-phenyl-1H-pyrrol-2-yl)acetamide 
• 1015700-86-3 C₃₇H₄₇N₅O₄ 
• 7568-93-6 2-Amino-1-phenylethanol 
• 218966-74-6 S-1-(1,3-dioxoisoindolin-2-yl)-2-oxo-2-phenylethyl O-ethyl carbonodithioate 
• 14160-07-7 N-(1-bromo-2-oxo-2-phenyl-ethyl)-phthalimide 
• 1607823-29-9 C₂₆H₂₇NO₆S₂ 
• 186393-51-1 4-N-phenylamino-5-phenylpyrrolo[2,3-d]pyrimidine 
• 871671-45-3 5-phenylpyrrolo-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one 
• 208459-81-8 4-chloro-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine 
• 54760-24-6 2-amino-4-phenyl-1H-pyrrole-3-carboxylic acid amide 

Relevant academic research and scientific papers

An environmentally benign solvent/catalyst-free one-pot synthesis of N-substituted phthalimides via Aza-wittig reaction

For the first time an environmentally benign solvent/catalyst-free protocol for the synthesis of a variety of N-substituted phthalimides is submitted. It involves a one-pot coupling of nascent phosphazene generated in situ with phthalic anhydride. The protocol is novel in (1) avoiding toxic solvents, (2) no catalyst is employed and (3) no isophthalimide is formed as noted in the prevailing solution phase/catalysed methodology. Iranian Chemical Society 2012.

The preparation and in vitro antiproliferative activity of phthalimide based ketones on MDAMB-231 and SKHep-1 human carcinoma cell lines

The 'one pot' condensation reaction for the synthesis and potent antiproliferative inhibition of α-phthalimide based ketones is reported here. 2-Phthalimide-1-(4-fluoro-phenyl)ethanone (5) showed the best growth inhibition on human MDAMB-231 breast carcin

Palladium-catalyzed asymmetric hydrogenation of functionalized ketones

(Chemical Equation Presented) A novel catalytic system for asymmetric hydrogenation of functionalized ketones has been developed using a Pd/bisphosphine complex as the catalyst in 2,2,2-trifluoroethanol. The reaction exhibits high enantioselectivity, and

Ru-catalyzed asymmetric hydrogenation of α-phthalimide ketones and 1,3-diaryl diketones using 4,4′-substituted BINAPs

(Chemical Equation Presented) A family of tunable precatalysts [NH 2Et2][{Ru(4,4′-BINAP)Cl}2(μ-Cl) 3] was synthesized and used for highly enantioselective hydrogenation of phthalimide-protected amino ketones and

Dual Parasiticidal Activities of Phthalimides: Synthesis and Biological Profile against Trypanosoma cruzi and Plasmodium falciparum

Chagas disease and malaria are two neglected tropical diseases (NTDs) that prevail in tropical and subtropical regions in 149 countries. Chagas is also present in Europe, the US and Australia due to immigration of asymptomatic infected individuals. In the absence of an effective vaccine, the control of both diseases relies on chemotherapy. However, the emergence of parasite drug resistance is rendering currently available drugs obsolete. Hence, it is crucial to develop new molecules. Phthalimides, thiosemicarbazones, and 1,3-thiazoles have been used as scaffolds to obtain antiplasmodial and anti-Trypanosoma cruzi agents. Herein we present the synthesis of 24 phthalimido-thiosemicarbazones (3 a–x) and 14 phthalimido-thiazoles (4 a–n) and the corresponding biological activity against T. cruzi, Plasmodium falciparum, and cytotoxicity against mammalian cell lines. Some of these compounds showed potent inhibition of T. cruzi at low cytotoxic concentrations in RAW 264.7 cells. The most active compounds, 3 t (IC50=3.60 μM), 3 h (IC50=3.75 μM), and 4 j (IC50=4.48 μM), were more active than the control drug benznidazole (IC50=14.6 μM). Overall, the phthalimido-thiosemicarbazone derivatives were more potent than phthalimido-thiazole derivatives against T. cruzi. Flow cytometry assay data showed that compound 4 j was able to induce necrosis and apoptosis in trypomastigotes. Analysis by scanning electron microscopy showed that T. cruzi trypomastigote cells treated with compounds 3 h, 3 t, and 4 j at IC50 concentrations promoted changes in the shape, flagella, and surface of the parasite body similar to those observed in benznidazole-treated cells. The compounds with the highest antimalarial activity were the phthalimido-thiazoles 4 l (IC50=1.2 μM), 4 m (IC50=1.7 μM), and 4 n (IC50=2.4 μM). Together, these data revealed that phthalimido derivatives possess a dual antiparasitic profile with potential effects against T. cruzi and lead-like characteristics.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

MAP4K4 INHIBITORS

This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method of treatmentof cardiac conditions.In particular, the present invention relates to compounds of formula (I):

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

MAP4K4 INHIBITORS

This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, f

dipyrromethene-type compound, colorant compositions comprising the same, quencher for improving of contrast ratio comprising the same and color filter comprising the same

The present invention relates to a dipyrromethene-type compound. Specifically, the present invention relates to the dipyrromethene-type compound which is a dipyrromethene metal complex represented by chemical formula 1 or chemical formula 2, and dipyrrome